GLOBUS MEDICAL INC (GMED) is a publicly traded Healthcare sector company. As of May 20, 2026, GMED trades at $85.00 with a market cap of $10.71B and a P/E ratio of 110.28. GMED moved +5.14% today. Year to date, GMED is -7.12%; over the trailing twelve months it is +36.41%. Its 52-week range spans $51.79 to $101.40. Analyst consensus is strong buy with an average price target of $110.90. Rallies surfaces GMED's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Globus Medical Q1 Sales Soar 27% to $759.9M, EPS Up 66.6%: Globus Medical’s Q1 net sales jumped 27.0% year-over-year to $759.9 million, with base business up 13.2% excluding Nevro’s $82.7 million contribution. GAAP net income rose 64.7% to $124.3 million, GAAP EPS climbed 66.6% to $0.90, while non-GAAP EPS improved 64.7% to $1.12.
| Metric | Value |
|---|---|
| Price | $85.00 |
| Market Cap | $10.71B |
| P/E Ratio | 110.28 |
| EPS | $0.76 |
| Dividend Yield | 0.00% |
| 52-Week High | $101.40 |
| 52-Week Low | $51.79 |
| Volume | 2.15M |
| Avg Volume | 0 |
| Revenue (TTM) | $2.52B |
| Net Income | $102.98M |
| Gross Margin | 58.90% |
12 analysts cover GMED: 0 strong buy, 10 buy, 2 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $110.90.